Upregulation of Peroxiredoxin-2 in Well-Differentiated Pancreatic Neuroendocrine Tumors and Its Utility as a Biomarker for Predicting the Response to Everolimus

Upregulation of Peroxiredoxin-2 in Well-Differentiated Pancreatic Neuroendocrine Tumors and Its Utility as a Biomarker for Predicting the Response to Everolimus

Pancreatic neuroendocrine neoplasms (pNENs) account for 2–3% of pancreatic malignancies. Peroxiredoxins (Prdxs), which are major cellular antioxidants, are involved in multiple oncogenic signaling pathways. We investigated the role of peroxiredoxin-2 in QGP-1 human pNEN cell line and patient-derived...

Full description

Bibliographic Details
Main Authors: Eui Joo Kim, Yoon Jae Kim, Hye In Lee, Seok-Hoo Jeong, Hyo Jung Nam, Jae Hee Cho
Format: Article
Language:English
Published: MDPI AG 2020-11-01
Series:Antioxidants
Subjects:
pancreatic neuroendocrine neoplasm
peroxiredoxin
mTOR inhibitor
everolimus
Online Access:https://www.mdpi.com/2076-3921/9/11/1104

Similar Items

Similar Items